Cesca Therapeutics, Inc.
| Nasdaq: KOOL
Cesca Therapeutics, Inc. is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It is engaged in developing and manufacturing automated blood and bone marrow processing systems and companion disposable products that enable the separation, processing and preservation of cell and tissue therapy products. The company's core offerings include The SurgWerKs Platform, a proprietary stem cell therapy point-of-care kit system for treating vascular and orthopedic indications that integrate the following indication specific systems: - Cell harvesting - Cell processing and selection - Cell diagnostics - Cell delivery; The AXP AutoXpress Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP MarrowXpress and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood; The MarrowXpress Platform (MXP), a derivative product of the AXP and its accompanying disposable bag set, isolates and concentrates stem cells from bone marrow; The Res-Q 60 (Res-Q) Platform, a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma; and The BioArchive System, an automated cryogenic device, used by cord blood stem cell banks in various countries for cryopreserving and archiving cord blood stem cell units for transplant. The company was founded in 1986 and is headquartered in Rancho Cordova, CA.